Skip to content
Atlas Research Compounds

Immune function

TA1 Research Overview

A PubMed-backed overview of thymosin alpha 1 across immune modulation, infection, sepsis, oncology, and evidence maturity.

10 minute read

Evidence breadth

Thymosin alpha 1 is one of the catalog entries with a substantial clinical and review literature. Phase 3 expands its verified page set across sepsis, hepatitis, oncology, COVID-era reports, and immune-modulation reviews.

That breadth should not be mistaken for one universal conclusion. Indication, comparator, dosing context, and endpoint selection drive interpretation.

Why it anchors the immune hub

TA1 connects innate and adaptive immune topics, making it a natural anchor for the immune-function hub and the TA1-versus-thymulin comparison.

Atlas keeps TA1 separate from thymulin because both are thymic-context peptides but not interchangeable entities.

Sources and further reading

  1. 01

    Thymosin alpha 1 literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source

Research map

Compound: Thymosin Alpha 1Compound: ThymulinCompound: GHK-CuStudy PMID 40599771: Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysisStudy PMID 37845598: The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regressionStudy PMID 39814420: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial.Topic hub: Immune FunctionTopic hub: RecoveryTopic hub: Peptide ResearchComparison: TA1 vs. ThymulinComparison: GHK-Cu vs. TA1